Results 251 to 260 of about 42,293 (332)

Obesity significantly elevates thromboembolism risk in severe trauma, yet essential resuscitation with TXA and erythrocytes remains safe. [PDF]

Eur J Trauma Emerg Surg
Erdle B, Knoll M, Wagner FC, Frodl A, Diallo TD, Kalbhenn J, Schmal H, Mühlenfeld N.   +7 more
europepmc   +1 more source

Proton Pump Inhibitor‐Induced Fundic Gland Polyps With Massive Bleeding Regressed on Alternative Histamine 2 Receptor Antagonist Therapy

DEN Open, Volume 6, Issue 1, April 2026.
Abstract We report a case of massive bleeding from proton pump inhibitor (PPI)‐induced fundic gland polyps (FGPs) that regressed after switching to a histamine‐2 receptor antagonist (H2RA). A 46‐year‐old man with antiphospholipid syndrome had been receiving warfarin and lansoprazole for 4 years.
Ryosuke Ikeda, Hiroaki Kaneko, Hiroki Sato, Yuto Matsuoka, Tomomi Hamaguchi, Aya Ikeda, Yoshihiro Goda, Soichiro Sue, Kuniyasu Irie, Shin Maeda   +9 more
wiley   +1 more source

Pathogen-Reduced Low-Titer Group O Whole Blood for Managing Massive Blood Loss in Prehospital and Early Hospital Settings: An In Vitro Study. [PDF]

J Clin Med
Sherstyukova E, Semenova J, Kandrashina S, Bogdanova A, Vinogradov I, Inozemtsev V, Shvedov M, Grechko A, Dokukin M, Kuzovlev A, Klychnikova E, Bulanov A, Kostin A, Sergunova V.   +13 more
europepmc   +1 more source

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study

American Journal of Hematology, Volume 101, Issue 3, Page 427-438, March 2026.
ABSTRACT The COMMANDS trial established luspatercept as a first‐line treatment for anemia in transfusion‐dependent lower‐risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS ...
Rami S. Komrokji, Sheida Hayati, Manuel Ugidos, Guillermo Garcia‐Manero, Matteo Giovanni Della Porta, Amer M. Zeidan, Valeria Santini, Uwe Platzbecker, Anita K. Gandhi, Rajasekhar N. V. S. Suragani   +9 more
wiley   +1 more source

The effect of post-operative continuous negative pressure therapy after debridement, antibiotics, and implant retention for acute periprosthetic joint infection. [PDF]

J Orthop Surg Res
Alayed H, Hsu AHS, Wu KT, Wu CT, Lin PC, Kuo FC.   +5 more
europepmc   +1 more source

The effect of transfusion of erythrocyte-containing blood components on the excretory function of the kidneys in children with anemia without bleeding

Polina S. Kuga, М. A. Kucher
openalex   +1 more source

Iron Overload With Erythrocyte Transfusion in Preterm Infants [PDF]

Santosh Kumar Panda, Pravati Jena, Femitha Pournami, Arathy Vijay   +3 more
openalex   +1 more source

Parvovirus B19-Induced Aplastic Crisis and Hemophagocytic Lymphohistiocytosis in a Child With Hereditary Spherocytosis. [PDF]

Cureus
Oyama M, Sakamoto K, Okura E, Saito S, Nakazawa Y.   +4 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 629-640, March 2026.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Pubertal Assessment and Growth in Patients With Hemoglobinopathies: A Longitudinal Multicenter Study on the Association With Ferritin Levels

European Journal of Haematology, Volume 116, Issue 3, Page 276-289, March 2026.
ABSTRACT Objectives Although Advancements in the Treatment of Hemoglobinopathies have Considerably Increased Life Expectancy, Hormonal and Pubertal Development Have Been Continuously Affected by Complications From Transfusion‐Related Iron Overload and Cytotoxic Therapies.
J. Dülberg, C. Sanchez, M.‐A. Burckhardt, L. Alacán Friedrich, V. Salow, A. Radauer‐Plank, A. Borgmann‐Staudt, H. Cario, M. Diepold, B. Drexler, L. Infanti, S. Kroiss, N. Dietliker, R. Merki, L. Njue, L. Oevermann, A. Rovó, K. Scheinemann, M. Schneider, M. Balcerek, T. Diesch‐Furlanetto   +20 more
wiley   +1 more source